Clinical trial
TGRX-326 Chinese Phase III for Advanced Non-small Cell Lung Cancer (NSCLC)
NCT06082635
Study timeline
Study start (actual)2023-12-14Date precision: day
Registry last updated2025-05-18
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Non Small Cell Lung Cancerunresolved
Interventions
TGRX-326DRUG
CrizotinibDRUG · verified · RxNorm: crizotinib
Sponsors & collaborators
Shenzhen TargetRx Co., Ltd.lead sponsor
Sun Yat-Sen University Cancer Centercollaborator
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT06082635 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.